BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today presented new data at the Alzheimer’s Association International Conference (AAIC), supporting a novel multi-marker approach to test for Alzheimer’s disease (AD).

马萨诸塞州比勒里卡（商业新闻短讯）--Quanterix Corporation（纳斯达克：QTRX）是一家通过超灵敏生物标志物检测促进科学发现的公司，今天在阿尔茨海默病协会国际会议（AAIC）上提供了新数据，支持一种新的多标志物方法来检测阿尔茨海默病（AD）。

For the first time, new data show that applying a combination of AD-relevant biomarkers with p-Tau 217 significantly reduces the intermediate zone of a two-cutoff p-Tau 217 test, while preserving high accuracy above 90%..

新数据首次显示，将AD相关生物标志物与p-Tau 217结合使用可显着降低双截止p-Tau 217测试的中间区域，同时保持90%以上的高准确度。。

Recent Alzheimer’s Association criteria for diagnosing Alzheimer’s recommends that plasma p-Tau 217 tests be designed with two cutoffs to confidently differentiate between patients with or without AD pathology. This two-cutoff approach maximizes the accuracy of a p-Tau 217 test but leaves a zone of intermediate risk between the two cutoffs representing inconclusive borderline amyloid status.

最近阿尔茨海默氏病协会诊断阿尔茨海默氏病的标准建议，血浆p-Tau 217测试应设计为两个临界值，以自信地区分患有或不患有AD病理的患者。这种双临界方法最大程度地提高了p-Tau 217测试的准确性，但在两个临界值之间留下了一个中间风险区域，代表了不确定的临界淀粉样蛋白状态。

It is desirable to reduce this intermediate region while preserving a test’s accuracy to reduce the number of patients receiving inconclusive results..

希望减少这个中间区域，同时保持测试的准确性，以减少接受不确定结果的患者数量。。

Quanterix investigated whether interrogating intermediate samples with a panel of additional Alzheimer’s-associated plasma biomarkers, including combinations of amyloid β 42, amyloid β 40, GFAP, and NfL, together with p-Tau 217 in an algorithm that provides a single risk score, would improve the amyloid classification of uncertain results compared to a stand-alone p-Tau 217 test.

Quanterix研究了在提供单一风险评分的算法中，用一组额外的阿尔茨海默氏病相关血浆生物标志物（包括淀粉样蛋白β42，淀粉样蛋白β40，GFAP和NfL的组合）以及p-Tau 217询问中间样品是否会改善不确定结果的淀粉样蛋白分类，与独立的p-Tau 217测试相比。

The research found that this multi-marker approach enabled accurate amyloid classifications for 151 of 228 previously uncertain results across a large, high-diversity cohort of symptomatic individuals, reducing the intermediate zone 3-fold from 31.2% to 10.5% compared to p-Tau 217 alone. This finding highlights a potential key benefit of a multi-marker approach to blood-based Alzheimer’s testing, which is to provide diagnostic certainty for a significantly greater number of patients undergoing evaluation for AD..

该研究发现，这种多标记方法能够对228个先前不确定的结果中的151个进行准确的淀粉样蛋白分类，这些结果跨越了一个大型的，高度多样性的有症状个体队列，与单独的p-Tau 217相比，中间区从31.2%降低到10.5%。这一发现突出了基于血液的阿尔茨海默氏病检测的多标记方法的潜在关键益处，即为大量接受AD评估的患者提供诊断确定性。。

“Quanterix’s Simoa technology is an exceptionally sensitive platform, which when combined with our digital p-Tau 217 assay, has provided a result for all samples tested,” said Masoud Toloue, CEO of Quanterix. “In over 2,000 samples tested, our LucentAD p-Tau 217 assay has yet to encounter a single result that is unreadable and combines this sensitivity with an overall accuracy above 90%.

Quanterix首席执行官Masoud Toloue表示：“Quanterix的Simoa技术是一种异常灵敏的平台，当与我们的数字p-Tau 217分析相结合时，可以为所有测试的样品提供结果。”在2000多个测试的样品中，我们的LucentAD p-Tau 217分析尚未遇到无法读取的单一结果，并且将这种灵敏度与总体准确度相结合，达到90%以上。

With these novel multi-marker results, we are leveraging the best of our p-Tau 217 test along with other AD-relevant biomarkers. We believe that a multi-marker approach is the next phase in the evolution of blood-based testing, not only for identifying and staging Alzheimer’s pathology, but also for informing important differential treatment pathways that include non-Alzheimer’s neurodegenerative diseases.

有了这些新颖的多标记结果，我们正在利用我们最好的p-Tau 217测试以及其他与AD相关的生物标记。我们认为，多标记方法是基于血液的检测发展的下一个阶段，不仅用于识别和分期阿尔茨海默氏病的病理，而且用于告知包括非阿尔茨海默氏病神经退行性疾病在内的重要差异治疗途径。

The latter is an important consideration given approximately 30% of Alzheimer’s patients have pathologies other than AD.”.

后者是一个重要的考虑因素，因为大约30%的阿尔茨海默病患者患有AD以外的疾病。”。

Quanterix is currently investing in further studies to evaluate multi-marker testing and expects to launch a multi-marker laboratory developed test later this year through its LucentAD product line. LucentAD consists of a menu of laboratory developed tests run under CLIA and focused on applications supporting Alzheimer’s diagnosis and treatment..

Quanterix目前正在投资进一步研究以评估多标记测试，并预计今年晚些时候通过其LucentAD产品线启动多标记实验室开发的测试。LucentAD包括一系列在CLIA下运行的实验室开发测试，重点是支持阿尔茨海默氏病诊断和治疗的应用程序。。

This work is being presented in a virtual poster entitled, “Multi-Marker Approach to Reducing the Intermediate Range of a High Accuracy 2-Cutoff Plasma p-Tau 217 Test for Amyloid Detection,” poster 95706, throughout AAIC. Quanterix will be at AAIC (7/28 – 8/1) at booth #730. Interested parties can schedule time to meet with Quanterix team members onsite using the event website: (https://www.quanterix.com/conferences/alzheimers-association-international-conference-aaic-2024/)..

这项工作正在一张名为“减少淀粉样蛋白检测的高精度2截止血浆p-Tau 217测试中间范围的多标记方法”的虚拟海报中呈现，海报95706贯穿整个AAIC。Quanterix将于AAIC（7月28日至8月1日）在#730号展位展出。感兴趣的各方可以通过活动网站安排时间与Quanterix团队成员进行现场会面：(https://www.quanterix.com/conferences/alzheimers-association-international-conference-aaic-2024/)。。

To learn more about Lucent Diagnostics, visit: https://www.lucentdiagnostics.com/.

要了解有关朗讯诊断的更多信息，请访问：https://www.lucentdiagnostics.com/.

For more information about Quanterix’s work in neurology, visit: https://www.quanterix.com/therapeutic-areas/neurology/.

有关Quanterix在神经病学方面工作的更多信息，请访问：https://www.quanterix.com/therapeutic-areas/neurology/.

About Quanterix

关于Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods.

从发现到诊断，Quanterix的超灵敏生物标志物检测正在推动突破，只有通过其无与伦比的灵敏度和灵活性才能实现。该公司的Simoa®技术为血液，血清或血浆中的早期生物标志物检测提供了金标准，能够量化远低于常规类似方法定量限（LoQ）的蛋白质。

Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals.

其业界领先的精密仪器、数字免疫分析技术和CLIA认证的加速器实验室支持了促进神经病学、肿瘤学、免疫学、心脏病学和传染病疾病理解和管理的研究。近二十年来，Quanterix一直是科学界值得信赖的合作伙伴，为2900多种同行评审期刊上发表的研究提供了动力。

Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn..

有关这家位于马萨诸塞州Billerica的公司的更多信息，请访问https://www.quanterix.com或者在Twitter和LinkedIn上关注我们。。